B
ullous pemphigoid (BP) is the most common autoimmune blistering skin disease; it mainly affects people in their late 70s. 1 Patients with BP tend to be multimorbid: in a recent study 84% of subjects with BP also had at least 2 other chronic diseases. 2 The reported prevalence of diabetes among patients with BP varies between 8% and Table I ; available at http://www. jaad.org), and diabetes is among the 3 most common comorbidities in patients with BP. 2 Polypharmacy is common among patients with BP and appears to be associated with heightened mortality. 3 Several medications are suspected to predispose for development of BP. 4 Most recently, dipeptidyl peptidase 4 inhibitors (DPP4is), which constitute a class of oral antihyperglycemic drugs used for the treatment of diabetes, have been shown to increase the risk of BP significantly. The DPP4i vildagliptin has been particularly implicated. [5] [6] [7] Although neither national nor international guidelines currently address this issue, the recent data suggest that a DPP4i should not be used in patients with BP. 5, 7 In our previous study, the use of metformin was not associated with increased risk of BP. 5 However, given the common comorbidity between BP and diabetes, 2 it is of great importance to identify any risks associated with the use of other classes of diabetes medication in patients with BP.
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METHODS
Populations and databases
This was a retrospective registry study of all patients in Finland in whom BP was diagnosed between January 1, 1997, and December 31, 2013 . Patient records were obtained from the Finnish Care Register for Heath Care (formerly called the Hospital Discharge Register), which contains data on the diagnosis codes of hospitalized patients from the year 1994 onward and outpatient visits from 1998 onward. Data for the Care Register for Heath Care are collected from all hospitals maintained by local authorities, municipal federations, and the central government, as well as from the largest private hospitals. Similarly to in our previous study, 8 patients were selected on the basis of a diagnosis of BP (International Classification of Diseases [ICD] , Ninth Revision, codes 6945A and 6945B and ICD, 10th Revision, code L12.0]. The control population in this study was constructed from patients in whom basal cell carcinoma (BCC) had been diagnosed (ICD, Ninth Revision, codes 1730A to 1739A and ICD, 10th Revision, codes C44.01, C44.11, C44.21, C44.31, C44.41, C44.51, C44.61, C44.71, C44.81, and C44.91) . For each case patient with BP, 4 controls were randomly selected from the group of controls with BCC and matched by sex, age, and year of diagnosis (within 2 years). For both BP and BCC, we used the first diagnosis that was found in the database. We also collected data on all subjects' other diagnoses. All patients younger than 40 years were excluded from the study because BP is rare in younger age groups. 1 Data on the drugs used by patients in both groups were obtained from the Social Insurance Institution of Finland, which is a nationwide registry that includes reliable data on all drugs reimbursed from the year 1995 onward. Therefore, to obtain data on all reimbursed drugs for 2 years before diagnosis of BP or BCC, only patients who received their diagnosis between 1997 and 2013 were included in the present study. The unique personal identification number given to every Finnish citizen was used to combine the data from the Care Register for Heath Care and the Social Insurance Institution databases. Drugs were classified according to the Anatomical Therapeutic Chemical classification system and data were collected using its codes. Diabetes drugs were classified into the following pharmacologic subgroups: sulfonylureas (A10BB); heterocyclic sulfonamides (A10BC); combinations of oral glucoselowering drugs (A10BD); a-glucosidase inhibitors (A10BF); thiazolidinediones (A10BG); glucagon-like peptide 1 analogues (A10BJ); sodium-glucose cotransporter 2 inhibitors (A10BK); and other blood glucoseelowering drugs, excluding insulins (A10BX). Every drug in each of these subgroups was also examined individually. Because metformin, DPP4i, and insulin preparations were not to be included in the present analysis, records for patients who were receiving metformin, DPP4i, or insulin as monotherapy or in combinations were excluded. Where data were examined by drug class, the observation period started from the date of approval in Finland of the first available drug in the class. The dates of approval were obtained from the website of the Finnish Medicines Agency (www.fimea.fi).
Statistical analysis
The characteristics of the study population are presented as proportions and means. The associations between diabetes drugs and BP were evaluated by using a conditional logistic regression model and presented with odds ratios and 95% confidence intervals. All statistical analyses were performed with SAS software (version 9.4, SAS Institute, Inc, Cary, NC). All 2-sided P values less than .05 were considered statistically significant.
RESULTS
The database search returned records for 4524 patients with BP who were treated in Finnish hospitals between the years 1987 and 2013. The present analysis included a subgroup of 3397 patients with BP who received a diagnosis of BP between the years 1997 and 2013. A total of 66,138 cases of BCC were identified. Of these, 12,941 were randomly selected to comprise the control group and were matched to cases in the BP group on the basis of age, sex, and year of diagnosis in a 4:1 ratio. Because of the absence of drug reimbursement data on some of the controls (who had BCC), 579 patients with BP had fewer than 4 controls.
Both type 1 diabetes and type 2 diabetes were significantly more common in the patients with BP than in the controls (Table I) . Because of unspecific diagnosis codes used, some cases were classified as diabetes of unspecified type.
In total, 582 of the patients with BP (17.1%) and 1555 of the controls (12.0%) had used at least 1 diabetes medication other than insulin. After adjustment for diabetes and several neurologic diseases, no association with risk of development of BP was found for metformin-thiazolidinedione combination therapy regimens, sulfonylureas, thiazolidinediones, or ''other'' diabetes drugs (guar gum and repaglinide) (Table II) . No heightened risk was seen when patient data were stratified by sex (Supplemental Table II ; available at http://www.jaad.org).
DISCUSSION
Previous studies reporting the prevalence of diabetes in patients with BP were mainly based on hospital data (Supplemental Table I ). Our results are in line with those of a Danish population-based study in which diabetes was found in 23% of patients with BP. 9 However, we found type 1 diabetes to be much less common (in 0.9% of patients) than in the Danish study (7.1%). There are no other studies reporting the exact prevalence of type 1 diabetes in patients with BP because the type of diabetes was mostly unspecified in the study from United States. 10 To the best of our knowledge, no previous nationwide registry study has shown that conventional oral antidiabetics are not associated with an increased risk of BP (see the Supplemental Material for the literature search strategy; available at http:// www.jaad.org). Previously, diabetes medications other than DPP4i have been studied only as a small part of a British study in which 9 patients with BP (10.5%) were taking orally administered hypoglycemics compared with 6 of the controls (4.5%). 4 A hospital-based study from Singapore reported that 5 patients with BP (4.8%) used either sulfonylurea, metformin, or acarbose compared with 22 of the controls (7.0%), but newer diabetes medications such as DPP4i were not analyzed.
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In general, BP occurs more often in women than in men. 1 In this study, no sex differences were found in the risk of development of BP after exposure to diabetes medication. Studies of DPP4i-associated risk of development of BP are contradictory: a hospital-based Swiss-French study found a greater risk among males. 7 By contrast, our recent Finnish nationwide registry study found a 3-fold greater risk of development of BP in women who are using any DPP4i than in men and a trend toward a heightened risk in women who are using vildagliptin. 5 EudraVigilance is a database of the European Medicines Agency in which suspected adverse drug reactions (ADRs) reported by national medicines regulatory authorities and pharmaceutical companies are collected. In the EudraVigilance database (up to February 2018), 0% to 3.8% of all skin-and subcutaneous tissueerelated ADRs reported by health care professionals and involving conventional oral antidiabetics and injectable incretin mimetics were classified as pemphigoid (Supplemental Table III ; available at http://www.jaad.org). In contrast, 51% of reported skin-and subcutaneous tissueerelated ADRs involving vildagliptin were pemphigoid. Thus, the data obtained from EudraVigilance align with our results (http://www. adrreports.eu/).
Recent studies have added to our knowledge of the association between DPP4i medication use and BP risk. [5] [6] [7] Currently, it is not known whether DPP4i-associated BP is a drug-induced or rather a drugaggravated condition, 5 although in some cases clinical remission of BP has been reported following withdrawal of a DPP4i. 7 When an adverse drug reaction is suspected, the medication that is a candidate cause should be withdrawn. This situation often presents a complex scenario for the clinician treating comorbid BP and diabetes because the oral corticosteroids that are often used to treat moderateto-severe BP 1 tend to elevate blood glucose level. It has been shown that metformin monotherapy is not associated with increased risk of BP. 5 However, if the DPP4i treatment is withdrawn, metformin alone may not be sufficient to control hyperglycemia in these patients. 12 Our results suggest that other classes of oral antidiabetics can be used as substitutes for DPP4is without risk of further aggravation of BP symptoms.
A major strength of our study is the availability in the records of the Social Insurance Institution of Finland of information on reimbursed medications that patients have purchased. Another major strength is that our study utilized one of the largest-ever nationwide BP cohorts. 13 The present study has some limitations. Because we utilized routinely collected registry data, we have no certainty that all the BP cases were immunologically confirmed and no information regarding the timing of onset of the BP symptoms. The disease of patients without blistering or extensive symptoms may have been misdiagnosed, and it was not possible to analyze any relationship between glucagon-like peptide 1 and BP owing to the few patients who were using these medications. The use of patients with BCC as a control population may J AM ACAD DERMATOL VOLUME 79, NUMBER 6 have introduced some confounding factors because compared with age-and sex-matched controls with BCC, patients with BP are more likely to have diabetes.
In conclusion, our study shows that the investigated diabetes drugs are not associated with increased risk of BP in a Finnish patient database, indicating they can be safely used in this population. Generalization of these results to other populations will require further studies.
LITERATURE SEARCH METHOD
We conducted a literature search in PubMed (from 1947 to March 13, 2018) using the medical subject heading terms bullous pemphigoid and diabetes mellitus or hyperglycemia. A screen of the titles removed clearly irrelevant articles. Abstracts of the articles that remained were read to determine relevance. Original studies discussing bullous pemphigoid, comorbidities, and drugs used were included. In addition, manual review of the reference lists of certain articles, such as recent reviews on the field of bullous pemphigoid, were undertaken to identify additional publications for consideration. The search was conducted independently by 2 of the authors to ensure reproducibility. 
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